奥沙利铂联合替吉奥+信迪利单抗在胃癌中的疗效  

Efficacy of Oxaliplatin Combined with Tegafur+Sintilimab in Gastric Cancer

作　　者：吉正磊 赵明宏[1] 袁琳[1] JI Zhenglei;ZHAO Minghong;YUAN Lin(Department of Oncology,Jianhu County People's Hospital,Jianhu 224700,Jiangsu,China)

机构地区：[1]建湖县人民医院肿瘤科,江苏建湖224700

出　　处：《系统医学》2025年第3期162-165,共4页Systems Medicine

摘　　要：目的探讨胃癌治疗中使用奥沙利铂联合替吉奥+信迪利单抗的效果。方法非随机选取2021年1月—2024年4月在建湖县人民医院接受相关治疗的72例胃癌患者,按治疗方法不同分为采取奥沙利铂+替吉奥治疗的对照组(n=36)和采取奥沙利铂联合替吉奥+信迪利单抗治疗的观察组(n=36)。对比两组治疗效果、血清肿瘤标记物水平与不良反应发生情况。结果观察组客观缓解率为58.33%(21/36)、疾病控制率为86.11%(31/36),均高于对照组的33.33%(12/36)、61.11%(22/36),差异有统计学意义(χ^(2)=4.532、4.431,P均<0.05)。治疗后,两组血清肿瘤标记物(癌胚抗原、糖抗原125、糖类抗原199)水平均降低,且观察组均低于对照组,差异有统计学意义(P均<0.05)。两组不良反应(恶心呕吐、骨髓抑制、手足综合征、肝功能损害)总发生率对比,差异无统计学意义(P>0.05)。结论胃癌治疗中采用奥沙利铂联合替吉奥+信迪利单抗的疗效可靠,安全性较高,且可在一定程度上降低患者血清肿瘤标记物水平。Objective To investigate the effect of oxaliplatin combined with tegafur+sintilimab in the treatment of gastric cancer.Methods From January 2021 to April 2024,seventy-two patients with gastric cancer admitted to Jianhu County People's Hospital were non-randomly selected.According to different treatment methods,they were divided intothe control group(n=36)treated with oxaliplatin+tegafur and the observation group(n=36)treated with oxaliplatin combined with tegafur+sintilimab.The therapeutic effect,serum tumor marker levels and adverse reactions were compared between the two groups.Results The objective remission rate of the observation group was 58.33%(21/36),and the disease control rate was 86.11%(31/36),which were higher than 33.33%(12/36),61.11%(22/36)of the control group,the differences were statistically significant(χ^(2)=4.532,4.431,both P<0.05).After treatment,the levels of serum tumor markers(carcinoembryonic antigen,carbohydrate antigen 125,carbohydrate antigen 199)in the two groups decreased,and those in the observation group were lower than the control group,the differences were statistically significant(all P<0.05).There was no significant difference in the total incidence of adverse reactions(nausea and vomiting,bone marrow suppression,hand-foot syndrome,liver function damage)between the two groups(P>0.05).Conclusion Oxaliplatin combined with tegafur+sintilimab in the treatment of gastric cancer has reliable efficacy and high safety,and can reduce the level of serum tumor markers in patients to a certain extent.

关 键 词：胃癌 奥沙利铂 替吉奥 信迪利单抗 不良反应 

分 类 号：R73[医药卫生—肿瘤]